Bavarian Nordic Enters Clinical Trials with HIV Multiantigen Vaccine
Bavarian Nordic, (Kvistgaard, Denmark), has initiated a Phase 1–2 clinical study with its HIV vaccine candidate, MVA-BN HIV multiantigen.
Bavarian Nordic, (Kvistgaard, Denmark), has initiated a Phase 1–2 clinical study with its HIV vaccine candidate, MVA-BN HIV multiantigen.
Enrolment in a Phase 1–2 safety and immunogenicity study in 15 HIV-infected patients (CD4 counts >350 uL/mL) has begun in the United States. The first safety data is expected by the end of 2008 and immunogenicity data will be available during first half of 2009.
The MVA-BN HIV multiantigen vaccine encodes eight genes from HIV, including Nef, and thus represents a more advanced vaccine candidate compared to Bavarian Nordic’s previous MVA-based HIV vaccine candidates, MVA HIV nef and MVA-BN HIV polytope. In previous clinical studies with MVA HIV nef, Bavarian Nordic has demonstrated proof-of-concept for the MVA technology’s ability to control HIV replication. Furthermore, the vaccine was shown to be immunogenic and to induce a broad T-cell response to Nef. The MVA-BN HIV multiantigen builds on these positive results and represents an excellent opportunity to stimulate a broad immune response to the majority of the HIV proteins that will likely have important implications in a prophylactic and therapeutic setting for HIV.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
